Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Icahn School of Medicine at Mount Sinai—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.
Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's cancer service is ranked No. 8 in the nation by U.S. News & World Report® for 2024-25.
Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Icahn School of Medicine at Mount Sinai—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.
Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's cancer service is ranked No. 8 in the nation by U.S. News & World Report® for 2024-25.
Raja Flores, MD, discusses nuanced approaches to surgical care for lung cancer, neoadjuvent chemotherapy, the role of randomized clinical trials, treatment for mesothelioma, and more
Approximately 10 percent of pancreatic ductal adenocarcinoma is due to a hereditary or genetic predisposition, including variants in the breast and ovarian cancer syndrome genes BRCA1 and BRCA2.
A group of per- and polyfluoroalkyl substances (PFAS)—endocrine-disrupting chemicals commonly dubbed "forever chemicals" due to their ability to persist in the environment—has long been thought to contribute to cancer risk. A Mount Sinai ...
With findings that human leukocyte antigen-II (HLA-II) heterozygosity is associated with reduced risk of developing lung cancer, with particular benefits to smokers, Mount Sinai researchers add evidence to the theory of the immune system's ...
A three-year-old boy from Eritrea with tuberculosis and Wilms tumor received multidisciplinary care from specialists at Mount Sinai Kravis Children's Hospital. He has been doing well after surgery and chemotherapy.
Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive ...
The Tisch Cancer Institute (TCI), a National Cancer Institute-designated cancer center, employs a multidisciplinary approach to cancer research and treatment, with the goal of advancing clinical breakthroughs that help prevent and eradicate cancer.
Prostate cancer is the second leading cause of cancer death among men in the United States. For patients whose disease do not respond well to treatment, a Mount Sinai researcher is attempting to change that reality with his work on BRCA2 ...
A Mount Sinai researcher is delving deep into the roles of the enzyme stearoyl coenzyme A desaturase 1 (SCD1) in cell metabolism and death. Her findings could yield new ways to target the elusive enzyme, and in turn help devise new ways ...
At The Tisch Cancer Institute, we are committed to unraveling cancer behavior and biological mechanisms in order to enable development of effective therapies that are accessible to all patients and improve their lives.
Glioblastoma is among the deadliest cancers, and Mount Sinai researchers are making headway into uncovering mechanisms that could turn that disease around: microglia.
The decades-long research efforts of a consortium, led by Mount Sinai researchers, to deplete myelofibrosis stem cells altogether—instead of merely stopping proliferation—has received renewed funding.
Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different ...
In the United States, cholangiocarcinoma, or bile duct cancer, is relatively rare, although its incidence is growing for reasons experts have yet to identify. Because of its rarity, research into it has been scarce. But a Mount Sinai researcher ...
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.
The Mount Sinai Health System has received a $12,180,625 grant from the National Heart, Lung and Blood Institute to compare new treatment options for sickle cell disease and determine which work best for specific patients.
Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
In a phase 2 clinical trial that was the first of its kind, doctors found that some patients could be treated with a combination of chemotherapy and immunotherapy without the need to remove their bladder.
A first-of-its-kind study unveils how diabetes drives multiple myeloma growth and differences in survival outcomes for Black versus white patients with both conditions
Graft-versus-host disease is a complication of stem cell or bone marrow transplantation with few treatment options. But Mount Sinai researchers have been working on the problem for decades, bringing innovations to the field.
Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer ...
The Mount Sinai Acute GVHD International Consortium comprising 25 BMT centers uses pioneering proteomic techniques to identify and validate biomarkers for skin, gut, and steroid-resistant GVHD.
Tremendous progress has been made in improved survival and quality of life for multiple myeloma patients. Continued advancements in effective treatment options has changed the outlook for patients and physicians.
The Mount Sinai Health System’s esophagectomy program has received a three-star (excellent performance) overall composite score from the Society of Thoracic Surgeons (STS).
Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.
Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society ...
Nina Bhardwaj, MD, PhD, was honored with the 2022 ESMO Award for Immuno-Oncology from the European Society for Medical Oncology in recognition of her outstanding contributions to cancer immunology research.
The World Trade Center (WTC) Health Program at Mount Sinai has characterized differences in prostate cancer risk between that of responders to the attack and that of the general public.
The Tisch Cancer Institute continues to benefit from the addition of topflight investigators to its diverse research team from medical centers and laboratories around the world.
Jian Jin, PhD, continues to push frontiers in oncology research at The Tisch Cancer Institute (TCI), with his latest discoveries including advances in protein degradation in breast cancer and leukemia.
A recent study in pancreatic cancer provided evidence for immunoediting in human cancers, opening up the potential for cancer vaccines that could improve survival and outcomes.
The effects of ARID2 gene mutations are being explored for the first time in advanced melanoma, which not only sheds light on how those tumor cells become more aggressive, but also opens doors to better treatment and prevention strategies in the future.
Recent work with induced pluripotent stem cells has helped uncover complex mechanisms in myelodysplastic syndrome and acute myeloid leukemia for the first time. This discovery could pave the way for improving current treatments, or even for finding new ones.
At The Tisch Cancer Institute, we are investigating the complexities of cancer biology and behavior with the goal of improving the lives of those affected by cancer and minimizing its power.
Andrea Wolf, MD, Director of the New York Mesothelioma Program at the Mount Sinai Health System, has received the prestigious 2022 Irving J. Selikoff Lifetime Achievement Award from the Asbestos Disease Awareness Organization.
The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells—white blood cells that can be enlisted to fight off diseases—to kill multiple myeloma cells.
Dr. Joseph Sparano, 2024 OncLive Giant of Oncology in Breast Cancer, presents update on results from the TAILORx breast cancer trial at San Antonio Breast Cancer Symposium 2022
Raja M. Flores, MD, and Brian Housman, MD, have pioneered major modifications to the Ivor Lewis esophagectomy that make it less invasive and enable patients to recover more quickly.
Researchers at Mount Sinai’s Tisch Cancer Institute have identified a new gene that is essential to colon cancer growth and found that inflammation in the external environment around the tumor can contribute to the growth of tumor cells.
For the first time, scientists have identified a type of cancer cell in triple negative breast tumors, which is highly efficient in invading and colonizing distant organs but slow their growth upon colonization.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking ...
The Cardio-Oncology Program at The Mount Sinai Hospital, under the directorship of Gagan Sahni, MD, has been awarded Gold Center of Excellence status. This is the highest designation of certification from the International Cardio-Oncology ...
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle...
Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.
The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued ...
World Trade Center (WTC) first responders who underwent low-dose CT (computed tomography) lung screenings were three times more likely to have moderate-to-severe steatosis than others, a result much higher than expected.
Small-molecule inhibitors of the closely related cyclin-dependent kinases 4 and 6 (CDK4/6 is) that have shown success in treating patients with metastatic breast cancer have been only modestly effective against other tumor types.
Scientists led by Miriam Merad, MD, PhD, have shown for the first time that specific populations of macrophages promote tumor growth and contribute to immune evasion in early lung cancer lesions.
The search for effective new treatments for liver cancer has led Mount Sinai investigators to highly targeted compound libraries that include kinase inhibitors, histone modifying enzymes, and other small molecules used in combination with ...
A research team at The Tisch Cancer Institute, which focuses on the burgeoning field of cancer dormancy, has identified a promising strategy for preventing metastasis from occurring.
One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells lose the targeted antigen.
Investigators at The Tisch Cancer Institute are developing different types of personalized vaccines, including those that treat cancers with common cell mutations and those combined with checkpoint inhibitors.
Mount Sinai researchers led by Samir Parekh, MD, have found a family of three compounds that fit into a pocket on the SOX11 surface that interfere with DNA binding and block the mechanism by which mantle cell lymphoma develops.
Oren J. Becher, MD, was recently named Chief of the Jack Martin Division of Pediatric Hematology-Oncology, the Steven Ravitch Chair in Pediatric Hematology, and Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai.
Investigators Ramon Parsons, MD, PhD, and Jian Jin, PhD, have engineered a synthetic compound—a small molecule called MS21— that targets the PTEN/AKT pathway, one of the most commonly mutated pathways in human cancers.
The U.S. Food and Drug Administration's recent approval of the adjuvant use of nivolumab for muscle-invasive urothelial carcinoma may set a new standard of care.
In June 2021, clinician and researcher, Joseph A. Sparano, MD, joined The Tisch Cancer Institute as Deputy Director, where he will continue to lead clinical trials and improve treatments for breast cancer and cancers associated with HIV ...
We begin 2022 with a look at The Tisch Cancer Institute’s (TCI) latest discoveries by highlighting the work of our dedicated investigators. Their advances will bring our patients better health and longevity.
Gene signatures derived from lung carcinoma could potentially predict outcomes among individuals with small lung cancers detected by chest CT imaging, when those tumors cannot be distinguished visually as aggressive or indolent.
Fewer than 10 percent of potentially eligible patients undergo lung cancer screening, resulting in unnecessary illness and death. The new Chief of Pulmonary, Critical Care and Sleep Medicine at Mount Sinai Morningside wants to change that.
With a particular focus on breast cancer, Dr. Sparano presents on progress in reducing mortality, advancing precision medicine for improved outcomes, and addressing disparities in care and outcomes.
We begin 2022 with a look at The Tisch Cancer Institute’s (TCI) latest discoveries. In this report we highlight the work of our dedicated investigators who explore the complexity of cancer formation and metastasis and search for effective ways to stop it.
A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, supporting the need for increased use of screening to save lives, according to a Mount Sinai study published in JAMA ...
Dr. Becher is an expert in brain tumors in children, particularly diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain cancer. For more than a decade, his research has focused on identifying therapeutic targets to treat DIPG.
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature.
Matthew Galsky, MD, reported at the 2021 ASCO annual meeting that transurethral resection of bladder tumor + gemcitabine, cisplatin, plus nivolumab achieves stringently defined clinical complete response in a large subset of patients with ...
Charles Powell, MD, System Chief for Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine and CEO of the Mount Sinai-National Jewish Health Respiratory Institute, answers questions regarding anti-HER2 monoclonal ...
Dr. Matthew Galsky and colleagues identify genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder
The Ocular Oncology Service at NYEE is home to the most advanced forms of eye cancer treatments aimed at preserving life, preserving the eye, and saving sight
A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers.
Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers, has joined Mount Sinai Health System as Director of the Gastrointestinal Oncology Program
The Tisch Cancer Institute at Mount Sinai has been awarded $13 million as part of the renewal of its National Cancer Institute Cancer Center Designation
The results of this Phase 1 study support the use of rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia
With the approval of New York State, surgeries have recommenced. Benjamin J. Golas, MD, discusses the special precautions for cancer patients scheduled for surgery.
Augusto Rodriguez, MD, PhD, discusses a novel technology to detect liver cancer—liquid biopsy—as well as an overview of liver cancer’s causes, diagnosis, and treatment.
Lewis R. Silverman, MD, one of the foremost researchers in myelodysplastic syndrome, shares insights into the disease as well as the current state of research.
Metastatic hormone-sensitive prostate cancer (mHSPC) is deadly, with a reported median survival of less than 5 years. Historically, androgen deprivation therapy (ADT) has been the standard of care. The development of new therapeutic options, ...
A profile of Steven J. Burakoff, MD, Dean for Cancer Innovation at the Icahn School of Medicine at Mount Sinai and Chief of Pediatric Oncology at the Mount Sinai Health System
A Department of Medicine Grand Rounds presented by Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute, and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai
